Posted by Michael Wonder on 27 Jun 2023
CStone announces Gavreto (pralsetinib) sNDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion positive non-small cell lung cancer
27 June 2023 - The approval for the first-line treatment of RET fusion positive non-small cell lung cancer marks the third indication of Gavreto in Mainland China, and the eleventh new drug application approval that CStone has obtained in Greater China overall.
CStone Pharmaceuticals today announced that the National Medical Products Administration of China has approved the supplemental new drug application of Gavreto (pralsetinib), a selective rearranged during transfection (RET) inhibitor, for the first-line treatment of adults with locally advanced or metastatic RET fusion positive non-small cell lung cancer.
